GMTX Stock Price, Gemini Therapeutics, . Quote, Chart

Market Summary

USD32.13-0.05

Market Closed

-0.16%

GMTX Stock Price

View Fullscreen

GMTX RSI Chart

GMTX Valuation

Market Cap

794.3M

Price/Earnings (Trailing)

-9.86

Price/Sales (Trailing)

53.68

EV/EBITDA

-5.61

Price/Free Cashflow

-11.07

GMTX Price/Sales (Trailing)

GMTX Profitability

EBT Margin

-544.14%

Return on Equity

-23.84%

Return on Assets

-22.76%

Free Cashflow Yield

-9.03%

GMTX Fundamentals

GMTX Revenue

Revenue (TTM)

14.8M

GMTX Earnings

Earnings (TTM)

-80.6M

Earnings Growth (Yr)

-18.3%

Earnings Growth (Qtr)

-14.29%

Breaking Down GMTX Revenue

Last 7 days

5.7%

Last 30 days

5.9%

Last 90 days

-51.2%

Trailing 12 Months

3629.7%

How does GMTX drawdown profile look like?

GMTX Financial Health

Current Ratio

23.7

GMTX Investor Care

Shares Dilution (1Y)

24.86%

Diluted EPS (TTM)

-3.35

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	0	0	0	14.8M
2022	0	0	0	0
2021	0	0	0	0
2020	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Gemini Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Oct 26, 2022	leonard braden michael	sold	-47,025	2.09	-22,500	-
May 31, 2022	piekos brian	acquired	10,856	1.09	9,960	cfo
Apr 13, 2022	leonard braden michael	bought	291,604	1.5206	191,769	-
Apr 12, 2022	leonard braden michael	bought	75,075	1.365	55,000	-
Apr 12, 2022	leonard braden michael	bought	290,193	1.4243	203,744	-
Apr 11, 2022	leonard braden michael	bought	681,057	1.35	504,487	-
May 14, 2021	meyenburg jason patrick	bought	122,929	9.4561	13,000	president & ceo
May 14, 2021	piekos brian	bought	72,431	9.462	7,655	chief financial officer
Feb 05, 2021	tananbaum james b.	acquired	-	-	2,928,750	-
Feb 05, 2021	tananbaum james b.	acquired	15,000,000	10.00	1,500,000	-

Which funds bought or sold GMTX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Nov 14, 2022	Foresite Capital Opportunity Management V, LLC	unchanged	-	-121,000	3,994,000	11.99%
May 16, 2022	Amalgamated Financial Corp.	new	-	4,000	4,000	-%
May 16, 2022	Parametric Portfolio Associates LLC	sold off	-100	-126,000	-	-%

Are Funds Buying or Selling GMTX?

Are funds buying GMTX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own GMTX

No. of Funds

Unveiling Gemini Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	paradigm biocapital advisors lp	9.9%	2,385,857	SC 13G/A
Feb 13, 2024	bain capital life sciences opportunities iii, lp	5.5%	1,332,545	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 07, 2024	adage capital partners gp, l.l.c.	3.11%	750,000	SC 13G/A
Jan 25, 2024	atlas venture fund x, l.p.	5.8%	1,402,186	SC 13D/A
Dec 15, 2023	orbimed advisors llc	7.1%	1,702,237	SC 13D/A
Nov 13, 2023	ai dmi llc	13.74%	3,345,840	SC 13D/A
Sep 25, 2023	paradigm biocapital advisors lp	5.4%	1,235,918	SC 13G
Sep 21, 2023	atlas venture fund x, l.p.	7.0%	1,593,785	SC 13D/A
Jun 30, 2023	adage capital partners gp, l.l.c.	5.24%	1,162,624	SC 13G

Recent SEC filings of Gemini Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
May 03, 2024	4	Insider Trading
May 01, 2024	ARS	ARS
May 01, 2024	DEF 14A	DEF 14A
May 01, 2024	DEFA14A	DEFA14A
Apr 15, 2024	4	Insider Trading
Apr 11, 2024	144	Notice of Insider Sale Intent
Apr 11, 2024	4	Insider Trading
Apr 02, 2024	8-K	Current Report

Gemini Therapeutics, Inc. News

Latest updates

Gemini Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2021Q4	2021Q3	2021Q2	2020Q4	2020Q3
Revenue	-	-	-	138,508,000	34,148,000	17,323,500	499,000	334,333	169,667	5,000	40,253,333	80,501,667	120,750,000
Operating Expenses	5.9%	31,462,000	29,714,000	17,328,000	25,125,000	15,021,000	10,479,000	12,015,000	-20,327,000	18,450,000	16,320,000	9,794,000	7,949,000
S&GA Expenses	-100.0%	-	7,149,000	5,228,000	4,945,000	5,005,000	2,593,000	4,301,000	-9,414,000	4,995,000	5,478,000	2,096,000	1,222,000
R&D Expenses	5.0%	23,704,000	22,565,000	12,100,000	20,180,000	10,016,000	7,886,000	7,714,000	-10,913,000	13,455,000	10,842,000	7,698,000	6,727,000
EBITDA Margin	-5.5%	-5.43	-5.15	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	41,000	48,000	85,000	104,000	121,000	4,519,000	2,047,000
Income Taxes	-84.4%	5,000	32,000	24,000	23,000	-	-	-	-	-	-	-	-
Earnings Before Taxes	-14.4%	-26,944,000	-23,547,000	-15,923,000	-22,758,000	-11,244,000	-16,150,000	-9,580,000	-	-	-	-313,084	-499,411
EBT Margin	-5.5%	-5.44	-5.16	-	-	-	-	-	-	-	-	-	-
Net Income	-14.3%	-26,949,000	-23,579,000	-15,947,000	-22,781,000	-11,244,000	-16,150,000	-9,580,000	18,077,000	-18,551,000	-16,447,000	-14,315,000	-10,003,000
Net Income Margin	-5.5%	-5.45	-5.17	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-89.1%	-33,666,000	-17,799,000	-12,736,000	-35,495,000	-9,677,000	-9,711,000	-9,214,000	19,491,000	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Assets	-3.8%	354	368	376	384	244	200	106	113	124	92.00	156	172	189	156	122	-
Current Assets	-3.8%	352	366	374	382	242	198	105	113	124	90.00	155	171	189	5.00	2.00	-
Cash Equivalents	-4.9%	343	360	371	378	236	195	56.00	65.00	74.00	88.00	150	168	185	26.00	14.00	6.00
Net PPE	24.1%	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	0.00	0.00	0.00	0.00	0.00	-	-
Liabilities	-29.6%	16.00	23.00	18.00	13.00	11.00	24.00	1.00	6.00	13.00	15.00	15.00	15.00	18.00	30.00	5.00	-
Current Liabilities	-30.7%	15.00	21.00	14.00	10.00	10.00	23.00	1.00	6.00	13.00	13.00	13.00	12.00	14.00	25.00	1.00	0.00
Shareholder's Equity	-2.0%	338	345	359	371	233	177	105	107	112	125	141	158	171	5.00	5.00	0.00
Retained Earnings	-14.3%	-215	-188	-165	-150	-135	-112	-210	-207	-199	-65.39	-166	-148	-131	-112	-0.50	0.00
Additional Paid-In Capital	3.7%	554	534	524	522	368	289	315	314	312	1.00	308	306	303	91.00	6.00	0.00
Shares Outstanding	1.4%	25.00	24.00	24.00	23.00	20.00	17.00	1.00	1.00	1.00	1.00	4.00	4.00	-	-	-	-
Float	-	-	-	-	508	-	-	-	29.00	-	173	-	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Cashflow From Operations	-88.8%	-33,599	-17,796	-7,476	-12,724	-35,466	-9,665	-9,692	-9,194	-13,701	19,498	-16,097	-15,928	-15,007	-4,539	-190	-7,033	-9,881
Share Based Compensation	110.6%	4,058	1,927	1,270	1,309	1,024	993	382	382	332	-5,607	1,659	2,862	1,593	590	161	138	94.00
Cashflow From Investing	-2133.3%	-67.00	-3.00	-45.00	-12.00	-29.00	-12.00	-19.00	-20.00	-100	-7.00	120,689	-	-	-	-120,750	-	-
Cashflow From Financing	104.9%	15,900	7,758	460	153,855	77,306	148,815	22.00	86.00	55.00	-102,730	-1,250	-1,581	195,490	70.00	122,378	9.00	20,094

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

GMTX Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development expense	$ 23,704	$ 20,180
General and administrative	7,758	4,945
Total operating expenses	31,462	25,125
Loss from operations	(31,462)	(25,125)
Other income (expense), net:
Interest income	4,519	2,367
Other expense	(1)	0
Total other income (expense), net	4,518	2,367
Loss before income taxes	(26,944)	(22,758)
Income tax expense	(5)	(23)
Net loss and comprehensive loss	(26,949)	(22,781)
Net loss attributable to common stockholders-basic	(26,949)	(22,781)
Net loss attributable to common stockholders-diluted	$ (26,949)	$ (22,781)
Weighted-average common shares outstanding-basic	24,809,869	18,954,914
Weighted-average common shares outstanding-diluted	24,809,869	18,954,914
Net loss per share attributable to common stockholders-basic	$ (1.09)	$ (1.2)
Net loss per share attributable to common stockholders-diluted	$ (1.09)	$ (1.2)

GMTX Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 342,615	$ 360,382
Prepaid expenses and other current assets	9,333	5,280
Total current assets	351,948	365,662
Property and equipment, net	211	170
Right-of-use assets, operating leases	1,788	1,930
Other assets	235	234
Total assets	354,182	367,996
Current liabilities:
Accounts payable	5,269	12,629
Accrued expenses	8,816	8,145
Operating lease liabilities, current	767	665
Total current liabilities	14,852	21,439
Operating lease liabilities, non-current	1,259	1,436
Total liabilities	16,111	22,875
Commitments and contingencies (Note 13)
Stockholders' equity:
Common stock, $0.0001 par value; 100,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 24,695,885 and 24,360,233 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	2	2
Additional paid-in capital	553,663	533,764
Accumulated deficit	(215,594)	(188,645)
Total stockholders' equity	338,071	345,121
Total liabilities and stockholders equity	$ 354,182	$ 367,996

About Gemini Therapeutics, Inc.

0

WEBSITE	geminitherapeutics.com

Gemini Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Gemini Therapeutics, Inc.? What does GMTX stand for in stocks?

GMTX is the stock ticker symbol of Gemini Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Gemini Therapeutics, Inc. (GMTX)?

As of Fri May 17 2024, market cap of Gemini Therapeutics, Inc. is 794.31 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GMTX stock?

You can check GMTX's fair value in chart for subscribers.

What is the fair value of GMTX stock?

You can check GMTX's fair value in chart for subscribers. The fair value of Gemini Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Gemini Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for GMTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Gemini Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether GMTX is over valued or under valued. Whether Gemini Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Gemini Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GMTX.

What is Gemini Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, GMTX's PE ratio (Price to Earnings) is -9.86 and Price to Sales (PS) ratio is 53.68. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GMTX PE ratio will change depending on the future growth rate expectations of investors.